These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29768140)

  • 1. Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer.
    Liljenquist D; Bai G; Anderson GF
    N Engl J Med; 2018 May; 378(20):1857-1859. PubMed ID: 29768140
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 3. The new drug war.
    Sherrid P
    US News World Rep; 2002 Dec; 133(21):41. PubMed ID: 12503485
    [No Abstract]   [Full Text] [Related]  

  • 4. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
    Ablavsky G; Larrimore Ouellette L
    JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
    [No Abstract]   [Full Text] [Related]  

  • 5. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs.
    Chakradhar S; Khamsi R
    Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215
    [No Abstract]   [Full Text] [Related]  

  • 6. Brand-name versus generic.
    Copeland KR; Boccuzzi SJ
    Health Aff (Millwood); 2007; 26(4):1198-9; author reply 1199. PubMed ID: 17630468
    [No Abstract]   [Full Text] [Related]  

  • 7. Prozac. A bitter pill.
    McLean B
    Fortune; 2001 Aug; 144(3):118-22, 126, 130-2. PubMed ID: 11499050
    [No Abstract]   [Full Text] [Related]  

  • 8. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 10. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 11. The U.S. Medicine Chest: Implications of Increased Reliance on China.
    Gibson R
    Ann Intern Med; 2018 Dec; 169(12):873-874. PubMed ID: 30535133
    [No Abstract]   [Full Text] [Related]  

  • 12. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 13. Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
    Gunter SJ; Kesselheim AS; Rome BN
    JAMA Intern Med; 2021 Aug; 181(8):1124-1126. PubMed ID: 33999110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the PPI sample for prescription pharmaceuticals.
    Kelly GG
    Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326
    [No Abstract]   [Full Text] [Related]  

  • 16. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 17. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 18. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulators can challenge deals that delay generic competition, says US Supreme Court.
    McCarthy M
    BMJ; 2013 Jun; 346():f3964. PubMed ID: 23783361
    [No Abstract]   [Full Text] [Related]  

  • 20. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
    Bell H
    Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.